Recent Updates — AGPU

Axe Compute Inc. completed the sale of its wholly owned subsidiary Helomics Corporation to DataMeds AI, Inc. on September 11, 2026. The transaction consideration consisted of 636,328 shares of DataMeds common stock, representing approximately 19.99% of DataMeds' outstanding shares immediately prior to closing, and a convertible promissory note with a principal amount of $1,363,672 at a conversion price of $1.00 per share. Axe Compute assumed responsibility for paying remaining base rent obligations under two Pittsburgh leases through their expiration dates. This divestiture finalizes the company's strategic transition from its former identity as Predictive Oncology Inc. to become a pure-play neocloud GPU-as-a-Service provider.

Axe Compute Inc. announced on July 22, 2026, that it secured over $1.3 billion in new customer contracts through its Axe Compute Build program across the United States and Europe. These five-year agreements exceed the company's mid-2026 goal of $1 billion in signed contracts. The company expects revenue from these engagements to begin in late Q4 2026, with prepayments occurring in Q3 2026, potentially boosting annual recurring revenue to over $384 million upon deployment. Axe Compute provides AI infrastructure through a design-deploy-own-operate model. Axe Compute is a neocloud AI infrastructure platform provider.

Axe Compute Inc. disclosed updated risk factors regarding its expansion into purchasing, owning, and operating GPU computing infrastructure in data center facilities. These updated risks supplement and supersede existing disclosures in the company's 2025 Form 10-K. Axe Compute Inc. operates in the GPU computing infrastructure and data center services industry.